Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas
Abstract:
Mouse monoclonal antibody L6 (IgG2a subtype) recognizes a ganglioside antigen expressed at the surface of cells from human non-small-cell lung carcinomas, breast carcinomas, and colon carcinomas. We now show that this antibody can lyse L6 antigen-positive human tumor cells in the presence of Leu-11b-positive human lymphocytes (i.e., mediate antibody-dependent cellular cytotoxicity) or human serum (mediate complement-dependent cytotoxicity) and that it can inhibit the outgrowth of an L6 antigen-positive human tumor transplanted onto nude mice.
Insights
Mouse monoclonal antibody L6 targets cancer cells expressing a specific ganglioside antigen. This antibody demonstrates effectiveness in antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and inhibiting tumor growth in vivo.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Monoclonal antibody L6 (IgG2a subtype) targets ganglioside antigens on human tumor cells.
- These antigens are found on non-small-cell lung, breast, and colon carcinomas.
Purpose of the Study:
- To evaluate the cytotoxic potential of monoclonal antibody L6 against L6 antigen-positive tumor cells.
- To assess the in vivo efficacy of monoclonal antibody L6 in inhibiting tumor growth.
Main Methods:
- Antibody-dependent cellular cytotoxicity assays using Leu-11b-positive human lymphocytes.
- Complement-dependent cytotoxicity assays using human serum.
- In vivo tumor inhibition studies in nude mice xenograft models.
Main Results:
- Monoclonal antibody L6 mediates significant lysis of L6 antigen-positive tumor cells via ADCC and CDC.
- The antibody effectively inhibits the outgrowth of L6 antigen-positive human tumors in nude mice.
Conclusions:
- Monoclonal antibody L6 exhibits potent anti-tumor activity through both immune-mediated and direct cytotoxic mechanisms.
- Antibody L6 shows promise as a therapeutic agent for carcinomas expressing the L6 ganglioside antigen.
